Temelimab as a Disease Modifying Therapy in Patients With Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID 19 or Postacute Sequelae of COVID-19 (PASC) Syndrome
Latest Information Update: 21 May 2024
At a glance
- Drugs Temelimab (Primary)
- Indications Post acute COVID 19 syndrome
- Focus Biomarker; Therapeutic Use
- Sponsors GeNeuro
- 16 May 2024 Status changed from active, no longer recruiting to completed.
- 11 Dec 2023 According to a GeNeuro media release, the Independent Data Monitoring Committee met to review the unblinded safety and efficacy data of the first 90 patients after three months of treatment which included an analysis for futility, the IDMC recommended to "continue the trial without any modifications".
- 28 Nov 2023 According to a GeNeuro media release, over 200 patients randomized in this trial and topline results are expected in June 2024.